|
WO2020163523A2
|
|
Targeting cd24-siglec interactions for treating subjects with prediabetes or diabetes
|
|
WO2020163529A1
|
|
Targeting cd24-siglec interactions for the treatment and prevention of nonalcoholic steatohepatitis
|
|
CA3102374A1
|
|
Methods of use of cd24 for the prevention and treatment of leukemia relapse
|
|
WO2019222082A1
|
|
Anti-cd24 compositions and uses thereof
|
|
EP3762014A1
|
|
Methods of use of soluble cd24 for treating acquired immune deficiency syndrome (hiv/aids)
|
|
AU2019214865A1
|
|
Mutant anti-CTLA-4 antibodies with improved immunotherapeutic effect but attenuated adverse effects
|
|
US2020197485A1
|
|
Methods of use of soluble cd24 for treating immune related adverse events in cancer therapies
|
|
US2020181235A1
|
|
Methods of use of soluble cd24 for neuroprotection and remyelination
|
|
KR20190126801A
|
|
How to use soluble CD24 to treat systemic lupus erythematosus
|
|
CN109715210A
|
|
CD80 and CD86 binding protein composition and application thereof
|
|
EP3411062A1
|
|
Use of cd24 proteins for treating leptin-deficient conditions
|
|
AU2016370648A1
|
|
Chimeric and humanized anti-human CTLA4 monoclonal antibodies and uses thereof
|
|
BR112017022394A2
|
|
use of cd24 to lower cholesterol levels of low density lipoproteins
|
|
CA2795823A1
|
|
Cd24 proteins and use thereof in treating rheumatoid arthritis
|
|
WO2011068563A1
|
|
Uses of hypoxia-inducible factor inhibitors
|
